Clinical Trial Update: GEM05 for Patients With Multiple Myeloma More Than 65 Years Old [Phase 3]

View source ↗

Summary

GEM05's Phase 3 trial in patients with multiple myeloma aged over 65 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GEM05

Snippet

Sponsor: PETHEMA Foundation | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED